Exploring the exosome-nanosome combinatorial platform as a novel, universal, and ideal nanoparticle-based drug delivery system

探索外泌体-纳米体组合平台作为一种新颖、通用、理想的基于纳米颗粒的药物递送系统

• 批准号: 22K20705
• 负责人: タン ロジャー・サルバシオン
• 金额: $ 1.83万
• 依托单位: Hokkaido University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Research Activity Start-up
• 财政年份: 2022
• 资助国家: 日本
• 起止时间: 2022-08-31 至 2024-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-22K20705/
• 关键词: Exosome-nanosme; Exosome; Cancer cells; Nanoparticle; Nanosome; Drug Delivery System

During the first fiscal year of research implementation, production and isolation have been optimized to yield high number of exosomes. This part is important for the incorporation of "nanosome" as the number of "exosome-nanosome" platform to be produced is dependent on the produced exosomes. The amount of exosome produced between fed and starved cells were also determined to be different. Some exosome proteins are downregulated in the starved state. These are significantly important as the "exosome-nanosome" incorporation on different cells/organs can also be impacted significantly.The construction of the platform showed limitations on the incorporation of the "nanosome" and optimization (sizes, ligand composition, and the overall charge) seemed to be necessary.

在研究实施的第一个财政年度，生产和分离得到了优化，以产生大量的外泌体。这部分对于“纳米体”的掺入很重要，因为要产生的“外泌体-纳米体”平台的数量取决于产生的外泌体。进食和饥饿细胞之间产生的外泌体量也被确定为不同的。一些外泌体蛋白在饥饿状态下下调。这些非常重要，因为不同细胞/器官上的“外泌体-纳米体”掺入也会受到显着影响。平台的构建显示出“纳米体”掺入的局限性，并且优化（尺寸、配体组成和总电荷）似乎是必要的。